Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Micro-Bio-Immune (MBI) is a biotechnology company specializing in the development and distribution of micro-immunotherapy products designed to regulate the immune system. The company utilizes low-dose formulations of cytokines, growth factors, and nucleic acids to communicate with the immune system and restore its natural balance. MBI's approach focuses on sequential administration of these substances to mimic the body's physiological immune response. Their products are primarily used in the management of chronic infections, autoimmune conditions, and inflammatory disorders, providing a complementary therapeutic option for healthcare professionals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Micro Bio Immune.